Xencor | XNCR - Sales Revenues



Xencor reported $43.61M in Sales Revenues for its fiscal quarter ending in June of 2025.


Sales Change Date
AbbVie USD 15.42B 2.08B Jun/2025
Alnylam Pharmaceuticals USD 773.69M 179.5M Jun/2025
Amgen USD 9.18B 1.03B Jun/2025
Arrowhead Research USD 27.77M 514.94M Jun/2025
AstraZeneca USD 14.46B 867M Jun/2025
Biogen USD 2.6B 170M Jun/2025
Bristol-Myers Squibb USD 12.27B 1.07B Jun/2025
Cytokinetics USD 66.76M 65.16M Jun/2025
GlaxoSmithKline GBP 7.99B 470M Jun/2025
J&J USD 23.74B 1.85B Jun/2025
MacroGenics USD 22.24M 2.89M Jun/2025
Merck USD 15.81B 280M Jun/2025
Novartis USD 14.05B 821M Jun/2025
Pfizer USD 14.7B 980M Jun/2025
Regeneron Pharmaceuticals USD 3.68B 650M Jun/2025
Roche Holding CHF 31.64B 883M Dec/2024
Xencor USD 43.61M 10.88M Jun/2025